12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Molindone: Phase IIb started

Supernus began a double-blind, placebo-controlled U.S. Phase IIb trial to evaluate 3 doses of oral SPN-810 twice daily in about 120 ADHD patients ages 6-12 years...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >